Efficacy and Safety of SGLT2 Inhibitor on Insulin Resistance and Hyperglycemia in Werner Syndrome—A Case Report

    November 2025 in “ Journal of Diabetes Investigation ”
    Takashi Yagi, Daisuke Aotani, Chie Hasegawa, Yuki Shimizu, Hiroyuki Koyama, Yoshiro Maezawa, Koutaro Yokote, Tomohiro Tanaka
    TLDR Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.
    A 48-year-old man with Werner syndrome (WS) and hyperglycemia showed inadequate glycemic control with pioglitazone and metformin. Genetic analysis confirmed WS through compound heterozygous mutations in the WRN gene. The addition of dapagliflozin, an SGLT2 inhibitor, improved insulin resistance and glycemic control without adverse events. This case suggests dapagliflozin as a potential treatment option for diabetes associated with WS, highlighting its efficacy in ameliorating insulin resistance.
    Discuss this study in the Community →